GenePOC to attend ASM in Atlanta, USA from 7 to 11 June 2018
GenePOC will participate in the ASM (American Society for Microbiology) from June 7 to 11, in Atlanta, USA. Come visit our booth #1420 – Discover the power of the PIE and revogene instrument for...
View ArticleGenePOC to attend ID Week in San Francisco, USA from 3 to 7 of October 2018
Come visit our booth #1204 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
View ArticleGenePOC to attend AMP in San Antonio, USA from 31 of October to 3 of November...
Come visit our booth #1629 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
View ArticleGENEPOC ANNOUNCES HEALTH CANADA APPROVAL OF ITS CDIFF TEST
Read the Press Release here.
View ArticleGenePOC’s Investment in SMRT Panels Validated by Medicare Decision
Read the entire Genomeweb interview to learn more on GenePOC’s vision, future SMRT Panels (Specific, Medically appropriate, Reimbursement appropriate Test) in alignment with the Palmetto decision, and...
View ArticleGenePOC to attend MEDLAB in Dubai from February 4-7 2019
Come visit our booth # Z3 C33 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
View ArticleClik here to view.
GenePOC obtains FDA clearance for its GenePOC™ Strep A test
GenePOC Inc., member of the Debiopharm Group, is proud to announce its third test cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene device. Read the press release here.
View ArticleGenePOC to attend 29th ECCMID in Amsterdam, Netherlands, from April 13th to 16th
GenePOC will participate in the 29th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) from April 13th to 16th, in Amsterdam, Netherlands. Come to meet us at booth #1.54 and...
View ArticleGenePOC obtains CE marking for its GenePOC™ Carba test
GenePOC Inc., member of the Debiopharm Group, announces its third test to be CE marked, the GenePOC Carba assay, to be used with the revogene device. Read the press release here.
View ArticleGenePOC obtains FDA clearance for its GenePOC™ Carba test in the USA
GenePOC announces FDA clearance of its molecular diagnostic test for the detection and differentiation of the five most frequent gene sequences associated with carbapenem-non-susceptibility. Read here...
View Article
